Reynaldo Dietze

Dr. Dietze joined the Institute of Hygiene and Tropical Medicine (IHMT) / Universidade Nova de Lisboa, on March 2018, as an invited Full Professor, to lead the Teaching and Clinical Research Unit of Tropical Medicine.

Graduated in medicine in 1977 at the Biomedical Center of the Federal University of Espírito Santo, Brazil, Dr. Dietze completed his residency in Infectious and Parasitic Diseases at Hospital das Clínicas / University of São Paulo in 1980. A Master’s degree in 1983 and Doctorate’s degree in 1990 were awarded respectively by the Nucleus of Tropical Medicine, University of Brasilia and the Faculty of Medicine at the University of Sao Paulo. Dr. Dietze was the former Director of the Infectious Diseases Unit at the Federal University of Espírito Santo, Vitória, for 27 years, where he led a multidisciplinary team of researchers, studying epidemiology, microbiology, molecular biology and immunology of infectious diseases, in particular Tuberculosis, Leishmaniasis, Dengue and Zika virus infections. He is also an Honorary Associate Professor of Medicine and Director of the Fellowship Program of Infectious Diseases, at Duke University Medical Center, Durham, NC, USA. Dr. Dietze was the former President of the Brazilian Society of Tropical Medicine (2007-2009).

Dr. Dietze been involved, as a PI in several phase 2/3 clinical trials in Tuberculosis, Dengue, Schistosomiasis, Leishmaniasis, sponsored by pharma companies, the Walter Reed Army Institute of Research (WRAIR) and NIH-funded grants. Dr. Dietze is highly experienced in clinical trials design and has implemented multiple trials under IND from the US FDA. These are all consistent with Dr. Dietze’s new position as a Chair Professor at the IHMT where his is committed to improve the quality of clinical research in Tropical Medicine not only at his new host institution but also in African countries (Angola and Guinea Bissau) where the IHMT has collaborating sites.

1. Carnielli JBT, Monti-Rocha R, Costa DL, Molina Sesana A, Pansini LNN, Segatto M, Mottram JC, Costa CHN, Carvalho SFG, Dietze R. (2019). Natural Resistance of Leishmania infantum to Miltefosine Contributes to the Low Efficacy in the Treatment of Visceral Leishmaniasis in Brazil. Am J Trop Med Hyg 101(4):789-794. https://doi.org/10.4269/ajtmh.18-0949
2. Colangeli R, Jedrey H, Kim S, Connell R, Ma S, Chippada Venkata UD, Chakravorty S, Gupta A, Sizemore EE, Diem L, Sherman DR, Okwera A, Dietze R, Boom WH, Johnson JL, Mac Kenzie WR, Alland D; DMID 01-009/Tuberculosis Trials Consortium Study 22 Teams. (2018). Bacterial Factors That Predict Relapse after Tuberculosis Therapy. N Engl J Med. 30;379(9):823-833. https://doi.org/10.1056/NEJMoa1715849
3. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, da Silva RM, Gadelha Yamashita EP, de Oliveira Penna G, Lima Machado PR, Talhari S. (2011). Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 84(2):255-60.
4. Dietze R, Hadad DJ, McGee B, Molino LP, Maciel EL, Peloquin CA, Johnson DF, Debanne SM, Eisenach K, Boom WH, Palaci M, Johnson JL. (2008). Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 178(11):1180-5.
5. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R. (2006). Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 10(6):605-12.